Efruxifermin

Efruxifermin (EFX) is a weekly-injected Fc-FGF21 fusion in Phase 3 for metabolic dysfunction-associated steatohepatitis (MASH) - the renamed version of NASH, a fatty liver disease that progresses to cirrhosis and liver cancer in a meaningful fraction of patients. Three concurrent Phase 3 trials are running: SYNCHRONY Histology in non-cirrhotic F2/F3 fibrosis [1], SYNCHRONY Outcomes in compensated cirrhosis [2], and SYNCHRONY Real-World in non-invasively diagnosed patients [3]. The ownership picture changed in late 2025: Novo Nordisk completed its acquisition of Akero Therapeutics in December 2025 for $5.2B - $54/share cash at close plus a $6/share contingent value right (CVR) payable on U.S. regulatory approval of EFX for compensated MASH cirrhosis [10]. The competitive context matters: Madrigal's resmetirom (Rezdiffra) was FDA-approved in March 2024 for non-cirrhotic MASH and semaglutide (Wegovy) was FDA-approved in August 2025 for MASH with F2/F3 fibrosis [11], so EFX is no longer first-to-market and has to differentiate against both an oral pill and a market-dominant GLP-1. The bull case rests on HARMONY 96-week Phase 2b data published in Lancet 2025 showing 37% MASH resolution and 49% ≥1-stage fibrosis improvement at the 50mg dose vs 19%/19% placebo [4] - competitive with resmetirom's key data but lagging tirzepatide's SYNERGY-NASH numbers [12].

EFX is a novel biologic, never approved anywhere. FDA granted Fast Track designation for EFX in NASH/MASH in October 2021 [13]. The three Phase 3 trials are: SYNCHRONY Histology (NCT06215716) in non-cirrhotic MASH with F2/F3 fibrosis, n=~1,650, currently recruiting [1]; SYNCHRONY Outcomes (NCT06528314) in compensated MASH cirrhosis (F4), n=~2,150, recruiting, with a primary endpoint of time to first significant clinical event including decompensation, transplant, hepatocellular carcinoma, or MELD progression [2]; and SYNCHRONY Real-World (NCT06161571) in non-invasively diagnosed MASH/MASLD, n=~700, active not recruiting, measuring safety and exposure [3]. The histology Week 52 readout is the registration-enabling dataset for non-cirrhotic MASH, supporting a BLA filing if the dual histological endpoint hits. Company guidance: SYNCHRONY Real-World readout expected H1 2026; SYNCHRONY Histology expected H1 2027 [14]. The cirrhosis outcomes trial is a multi-year effort given slow clinical event accrual in compensated F4 patients. An October 2025 8-K disclosed updated Phase 2b SYMMETRY data in cirrhotic patients that informed the design of the Phase 3 cirrhosis program [5]. Earliest commercial inflection: 2027-2028 if non-cirrhotic Phase 3 hits clean. Since the Novo close, Akero operates as a wholly-owned subsidiary; the SYNCHRONY program continues under the same registrational design, now with Novo's commercial infrastructure behind it.

FGF21 is a hormone the liver releases when it's under metabolic stress - fasting, alcohol, or chronic fat overload. Its job is to tell the body to burn fat rather than store it, and to improve insulin sensitivity. In MASH, the liver is drowning in stored fat that triggers chronic inflammation; the cells that lay down scar tissue, called stellate cells, get activated and build collagen until the organ stiffens into fibrosis and eventually cirrhosis. FGF21 signals through FGFR1c (one of four fibroblast growth factor receptors) paired with beta-Klotho as an obligate co-receptor, which means it only acts on tissues that express both, mainly liver and adipose. Activation drives fatty acid oxidation, improves insulin sensitivity, and based on preclinical and Phase 2 data, directly suppresses fibrogenesis in stellate cells. The problem with native FGF21 is a half-life of about 1-2 hours, which makes it useless as a drug. Efruxifermin fuses an antibody Fc domain to FGF21, extending half-life enough for weekly subcutaneous dosing. How strong is the case? FGF21 biology is genetically validated, with human variants altering metabolic phenotypes, and animal models consistently show fibrosis improvement. But the class has buried programs: BMS discontinued pegbelfermin (a PEGylated FGF21, structurally distinct from EFX's Fc-fusion) in 2022 after a Phase 2b miss in cirrhosis [6]. The architectural difference matters: Fc fusion preserves FGFR1c-binding geometry more faithfully than PEGylation, which can sterically interfere with receptor engagement, and FcRn-mediated recycling generally gives cleaner PK and lower immunogenicity than large PEG conjugates. Akero's pharmacology and dosing appear better, and HARMONY 96-week is the only FGF21 Phase 2 to show durable MASH resolution and fibrosis improvement together at clinically meaningful rates [4].

SYNCHRONY Histology (NCT06215716) is the lead registration trial: ~1,650 non-cirrhotic MASH patients with F2 or F3 fibrosis, randomized to 50mg EFX weekly, 28mg EFX weekly, or placebo. Co-primary endpoints at Week 52 are MASH resolution without worsening fibrosis, and ≥1-stage fibrosis improvement without worsening MASH - the FDA-aligned dual histology endpoint that supported resmetirom's approval [1]. SYNCHRONY Outcomes (NCT06528314) is the longer-horizon asset: ~2,150 patients with compensated MASH cirrhosis (F4), 28mg EFX vs placebo, with a clinical-event primary endpoint of decompensation, transplant, hepatocellular carcinoma, or MELD progression [2]. This is the trial that anchors the CVR - Novo's contingent $6/share payout requires FDA approval in the compensated cirrhosis indication, where resmetirom is not approved. SYNCHRONY Real-World (NCT06161571) enrolled ~700 patients with non-invasively diagnosed disease using FibroScan and MRE rather than biopsy, primarily a safety and real-world exposure study [3]. The histology design is conservative and intentionally mirrors the resmetirom MAESTRO-NASH design. That's both a strength (regulatory predictability) and a vulnerability: inevitable network meta-analyses and physician-side cross-comparison with resmetirom even without a head-to-head arm [7]. The cirrhosis trial is the higher-risk, higher-value asset; pegbelfermin failed in exactly this population and the histological endpoint in F4 patients has a brutal failure history [8], with comparative fibrosis-regression evidence across MASH cirrhosis agents synthesized in recent network meta-analysis [15].

Our model gives this drug a 27% chance of eventually being approved. That number starts from the historical approval rate for Phase 3 drugs in this area - about 54% - then adjusts based on ten specific facts about the trial and its sponsor. The estimate is helped by strong earlier-phase results and more secondary endpoints than usual, but pulled down by heavier-than-usual blinding and the sponsor's thin or weak approval record. The remaining facts fall close to average for this stage and leave the estimate roughly where the base rate started.

Efficacy risk: Phase 2-to-Phase 3 attrition in MASH is real. Larger, less-controlled Phase 3 populations regularly show smaller effect sizes than tightly run Phase 2b trials, and the placebo histology response in MASH runs 10-20%, which has killed multiple programs. In cirrhosis, the histology endpoint has failed for pegbelfermin, selonsertib, simtuzumab, cenicriviroc, and others; fibrosis regression in F4 is biologically harder because the collagen matrix is more crosslinked and less plastic [8][15]. Competitive risk (the dominant concern post-approval landscape shift): semaglutide 2.4mg achieved 37% fibrosis improvement vs 22.5% placebo in ESSENCE and is FDA-approved for F2/F3 MASH as of August 2025 [11], and tirzepatide hit 51% fibrosis improvement and up to 73% MASH resolution at the 15mg dose in SYNERGY-NASH Phase 2 [12] with a likely Phase 3 readout pathway behind it. A physician already prescribing a GLP-1 for obesity in a MASH patient has limited incremental reason to add a weekly SC FGF21 injection unless EFX shows clearly superior fibrosis benefit, additivity, or value in GLP-1 failures. Akero/Novo has not publicly outlined a combination strategy, which is the most obvious commercial defense and may be the strategic logic of Novo's acquisition: pair EFX with semaglutide in the franchise. Safety risk: FGF21 analogs have shown injection site reactions, GI effects, and signals worth tracking in bone metabolism and IGF-1 elevation. Long-term safety in patients dosed continuously for years is unproven. Phase 2 safety database has been relatively clean, but Phase 3 exposure adds a zero to patient-year counts and is where rare on-target findings tend to surface. Execution risk: Running three concurrent Phase 3 trials totaling over 4,500 patients is operationally demanding. The outcomes trial will need 4-5+ years of event accrual. Enrollment now competes with real-world resmetirom and semaglutide prescribing in the eligible population. Financing risk is now moot: pre-acquisition Akero held ~$1.086B cash (June 30, 2025) with runway guided into 2028 [9], and post-close the program is funded directly off Novo's balance sheet. The investor-relevant residual is the CVR - $6/share contingent on cirrhosis approval, which is binary on SYNCHRONY Outcomes and a regulatory decision likely 5+ years out.

Signal, not noise. EFX is the highest-probability second entrant into the MASH market on injectable mechanism, and its Phase 2 data is the strongest in the FGF21 class to date. The M&A optionality previously priced into Akero has resolved - Novo Nordisk closed the acquisition in December 2025 at $54/share cash + $6 CVR [10], so the remaining investor exposure for non-Akero holders is via Novo Nordisk ($NVO) and via the CVR for legacy Akero holders. The specific data point that would change the read: SYNCHRONY Histology Week 52 readout. Watch for ≥1-stage fibrosis improvement above ~35% in pooled EFX arms - that would beat resmetirom's MAESTRO-NASH numbers and approach semaglutide's ESSENCE Phase 3 numbers, establishing EFX as best-in-class injectable for non-cirrhotic patients. If the rate lands in the 20-25% range, EFX becomes a second-line option behind semaglutide+resmetirom and the cirrhosis indication becomes the entire franchise (and the CVR's only realistic path to payout). The strategic rationale for Novo is likely the combination thesis: pair EFX with semaglutide for additive or complementary mechanism in the MASH/obesity franchise, which would also be the only commercially robust defense against tirzepatide. Check back: H1 2026 for SYNCHRONY Real-World readout (safety and real-world exposure, will move first); H1 2027 for SYNCHRONY Histology (the registration-enabling readout). Novo's quarterly reporting and any combination-trial disclosures are now the cadence-keepers rather than Akero standalone filings.